Lonza Group AG (LZAGY) Stock
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Lonza Group AG
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
Lonza Group AG is headquartered in CH.
Lonza Group AG (LZAGY) stock trades at $71.40 with a market capitalization of $50.80B. The stock is valued at a price-to-earnings (P/E) ratio of -376.36, price-to-book of 4.99, price-to-sales of 6.40. Over the past 52 weeks the stock has ranged between $58.53 and $73.85, and currently trades 3.3% below its 52-week high. It pays a dividend yielding 0.80%.
On profitability, Lonza Group AG generates a return on equity (ROE) of -1.28%, return on capital employed of 10.34%, an operating margin of 23.02%, a net profit margin of -1.74%.
In its most recent fiscal year, Lonza Group AG reported annual revenue of $6.5B, net profit of $949.0M, revenue has compounded at 7.7% a year over the last five years, profit at 1.8% a year.
The balance sheet shows a debt-to-equity ratio of 0.51, a current ratio of 1.66, total assets of $19.0B, $719.0M in cash and equivalents.
LZAGY has an average daily trading volume of 60,768 shares, a beta of 0.84.
Official website: www.lonza.com